[go: up one dir, main page]

DE69632726D1 - Verwendung von thiazerin-, oxazepin-, und diazepinverbindungen, zur hemmung von hiv, herpesvirus und zur unterdruckung der immunabwehr - Google Patents

Verwendung von thiazerin-, oxazepin-, und diazepinverbindungen, zur hemmung von hiv, herpesvirus und zur unterdruckung der immunabwehr

Info

Publication number
DE69632726D1
DE69632726D1 DE69632726T DE69632726T DE69632726D1 DE 69632726 D1 DE69632726 D1 DE 69632726D1 DE 69632726 T DE69632726 T DE 69632726T DE 69632726 T DE69632726 T DE 69632726T DE 69632726 D1 DE69632726 D1 DE 69632726D1
Authority
DE
Germany
Prior art keywords
herpesvirus
thiazerine
oxazepine
impress
inhibit hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69632726T
Other languages
English (en)
Other versions
DE69632726T2 (de
Inventor
Joseph Gracheck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69632726D1 publication Critical patent/DE69632726D1/de
Application granted granted Critical
Publication of DE69632726T2 publication Critical patent/DE69632726T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69632726T 1995-03-22 1996-01-26 Verwendung von thiazerin-, oxazepin-, und diazepinverbindungen, zur hemmung von hiv, herpesvirus und zur unterdruckung der immunabwehr Expired - Fee Related DE69632726T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US408431 1995-03-22
US08/408,431 US5612330A (en) 1994-03-07 1995-03-22 Methods for inhibiting and controlling viral growth
PCT/US1996/001098 WO1996029077A1 (en) 1995-03-22 1996-01-26 Use of thiazepine, oxazepine and diazepine coumpounds for inhibiting hiv, herpesvirus and suppressing the immune system

Publications (2)

Publication Number Publication Date
DE69632726D1 true DE69632726D1 (de) 2004-07-22
DE69632726T2 DE69632726T2 (de) 2004-10-14

Family

ID=23616271

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632726T Expired - Fee Related DE69632726T2 (de) 1995-03-22 1996-01-26 Verwendung von thiazerin-, oxazepin-, und diazepinverbindungen, zur hemmung von hiv, herpesvirus und zur unterdruckung der immunabwehr

Country Status (11)

Country Link
US (2) US5612330A (de)
EP (1) EP0817635B1 (de)
JP (1) JPH11502814A (de)
AT (1) ATE269084T1 (de)
CA (1) CA2211179A1 (de)
DE (1) DE69632726T2 (de)
DK (1) DK0817635T3 (de)
ES (1) ES2222477T3 (de)
MX (1) MX9705709A (de)
PT (1) PT817635E (de)
WO (1) WO1996029077A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612330A (en) * 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
CA2227688C (en) 1998-01-16 2007-07-31 James W. Critchfield Methods and compositions for inhibition of viral replication
US7015212B1 (en) 1999-05-12 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Thiazepine inhibitors of HIV-1 integrase
AU2001281142A1 (en) * 2000-08-16 2002-02-25 Japan Tobacco Inc. Diazepinones as antiviral agents
TW200607503A (en) * 2004-05-17 2006-03-01 Tibotec Pharm Ltd 1-heterocyclyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones
ATE479693T1 (de) 2004-09-17 2010-09-15 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
CN102731451B (zh) 2006-06-27 2015-07-29 武田药品工业株式会社 稠环化合物
US7960428B2 (en) 2006-09-29 2011-06-14 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as HIV inhibitors
CA2722211C (en) * 2008-04-24 2017-02-14 Indena S.P.A. Compositions for the treatment of vaginal infections with chronic inflammation
US9840515B2 (en) 2010-12-09 2017-12-12 University of Pittsburgh—of the Commonwealth System of Higher Education Protein kinase D inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013641A (en) * 1975-10-08 1977-03-22 Xerox Corporation Indolobenzoxazepines
AU5883794A (en) * 1993-01-20 1994-08-15 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Diazepin derivatives and antiviral compositions
US5489586A (en) * 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
US5612330A (en) * 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth

Also Published As

Publication number Publication date
WO1996029077A1 (en) 1996-09-26
US5612330A (en) 1997-03-18
DE69632726T2 (de) 2004-10-14
PT817635E (pt) 2004-10-29
JPH11502814A (ja) 1999-03-09
ATE269084T1 (de) 2004-07-15
CA2211179A1 (en) 1996-09-26
MX9705709A (es) 1997-10-31
US5703069A (en) 1997-12-30
EP0817635B1 (de) 2004-06-16
DK0817635T3 (da) 2004-09-27
EP0817635A1 (de) 1998-01-14
ES2222477T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
DE69632726D1 (de) Verwendung von thiazerin-, oxazepin-, und diazepinverbindungen, zur hemmung von hiv, herpesvirus und zur unterdruckung der immunabwehr
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
DK0805853T3 (da) Afstamningsdirigeret induktion af differentiering af humane mesenkyme stamceller
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
DE69513961D1 (de) Benzothiophen-, benzofuran- und indol-thiazepinone, oxazepinone und diazepinone als inhibitoren von zelladhäsion und hiv
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ES2188783T3 (es) Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.
EP1117672A4 (de) Antisense-modulation der survivin-expression
DE69715862D1 (de) Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DK0800399T3 (da) Kombineret terapeutisk behandling af hyperproliferative sygdomme
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
MX9201288A (es) Metodo de tratamiento.
MX9304133A (es) Nuevos derivados de los fosfolipidos.
PE73099A1 (es) Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales
ES2194225T3 (es) Regeneracion morfogenica inducida por peptidos de tejidos perceptores de sentidos.
YU169090A (sh) Tetra hidroimidazo (1,4) benzodiazepini
DE69635131D1 (de) Verwendung von beta-interferon zur behandlung der restenose
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee